Monoamine Neurotransmission

Monoamine neurotransmission refers to signalling by the biogenic monoamines: the catecholamines dopamine and noradrenaline (norepinephrine), the indolamine serotonin (5-HT), and the related transmitter histamine. These transmitters arise from a small number of brainstem and midbrain nuclei but project widely, acting largely as modulators of mood, arousal, reward, and movement, and they are central targets of antidepressant, antipsychotic, and stimulant pharmacology.

Definition

Monoamine neurotransmission is signalling mediated by biogenic amine transmitters (dopamine, noradrenaline, serotonin, and histamine) that are synthesised from aromatic amino-acid precursors, act predominantly through metabotropic receptors, and are inactivated by selective reuptake transporters and by enzymatic degradation via monoamine oxidase and catechol-O-methyltransferase.

Scope

The topic covers how monoamines are synthesised from amino-acid precursors, released, and cleared by reuptake transporters and the monoamine oxidases, and how they act through families of G-protein-coupled receptors. It frames the monoamine systems as the pharmacological substrate for many psychotropic drug classes, as descriptive reference material rather than treatment guidance.

Core questions

• How are dopamine, noradrenaline, and serotonin synthesised and metabolised?
• What functional roles do the diffuse monoamine projection systems serve?
• How do reuptake transporters and monoamine oxidase terminate monoamine signalling?
• Why are monoamine pathways the target of so many psychotropic medicines?

Key concepts

• Catecholamines and indolamines
• Dopamine receptors (D1- and D2-like families)
• Monoamine reuptake transporters (DAT, NET, SERT)
• Monoamine oxidase and catechol-O-methyltransferase
• Diffuse modulatory projection systems
• Reward and reinforcement signalling

Key theories

Monoamine hypothesis of mood disorders

The long-influential idea that depressed mood reflects reduced monoaminergic (serotonergic and noradrenergic) signalling, originally inferred from the actions of early antidepressants; it remains a reference framework while being recognised as an incomplete account.

Reward-prediction and dopamine signalling

The account that midbrain dopamine neurons signal discrepancies between expected and received reward, linking dopamine to reinforcement learning and to the neural mechanisms of addiction.

Mechanisms

Catecholamines are synthesised from tyrosine via L-DOPA to dopamine and then noradrenaline, while serotonin is made from tryptophan; the rate-limiting hydroxylase enzymes set transmitter supply. Released transmitter acts mostly on G-protein-coupled receptors, such as the D1-like and D2-like dopamine receptor families described by Beaulieu and Gainetdinov (2011), producing slow modulatory effects on target circuits. Signalling is terminated chiefly by selective plasma-membrane transporters (DAT, NET, SERT) that recapture the transmitter, with subsequent intracellular and extracellular breakdown by monoamine oxidase and catechol-O-methyltransferase, the metabolic routes reviewed by Eisenhofer et al. (2004). Because transporters and receptors are tractable drug targets, agents that block reuptake, inhibit degradation, or occupy receptors all modify monoamine tone.

Clinical relevance

Monoamine signalling is the presumed locus of action for several major drug classes, and dysregulated dopaminergic reward signalling is implicated in addiction (Hyman et al., 2006). The topic explains how these systems are organised and why they are pharmacologically important; it is reference material on mechanism and does not advise on the choice or use of any medication.

Evidence & guidelines

Receptor and transporter nomenclature follows IUPHAR consensus reviews; the cited Pharmacological Reviews articles provide the authoritative descriptions of dopamine receptors and catecholamine metabolism used here.

History

The biogenic amines were identified as central transmitters across the 1950s and 1960s, when histochemical mapping revealed discrete monoaminergic nuclei with diffuse projections. The observation that early antidepressant and antipsychotic drugs acted on these systems gave rise to the monoamine hypotheses of mood and psychotic disorders and established monoamines as a cornerstone of neuropsychopharmacology.

Debates

How adequate is the monoamine hypothesis of depression?

Although antidepressants act acutely on monoamine signalling, their delayed clinical effect and incomplete response point to downstream neuroplastic and glutamatergic mechanisms, so the monoamine account is now treated as partial rather than complete.

Seminal works

• beaulieu-2011
• eisenhofer-2004
• hyman-2006

Frequently asked questions

Which transmitters are the monoamines?

The biogenic monoamines include the catecholamines dopamine and noradrenaline (norepinephrine), the indolamine serotonin (5-HT), and histamine; all are amine transmitters made from aromatic amino-acid precursors.

How is monoamine signalling switched off?

Mainly by selective reuptake transporters that recapture the transmitter into the releasing neuron, followed by enzymatic breakdown via monoamine oxidase and catechol-O-methyltransferase.